G
Guillaume Lefèvre
Researcher at university of lille
Publications - 155
Citations - 2860
Guillaume Lefèvre is an academic researcher from university of lille. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 134 publications receiving 1966 citations. Previous affiliations of Guillaume Lefèvre include Lille University of Science and Technology.
Papers
More filters
Journal ArticleDOI
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
Christophe Corpechot,Olivier Chazouillères,Alexandra Rousseau,Antonia Le Gruyer,François Habersetzer,Philippe Mathurin,Odile Goria,Pascal Potier,Anne Minello,Christine Silvain,Armand Abergel,Maryline Debette-Gratien,Dominique Larrey,Olivier Roux,Jean-Pierre Bronowicki,Jérôme Boursier,Victor de Ledinghen,Alexandra Heurgué-Berlot,Eric Nguyen-Khac,Fabien Zoulim,Isabelle Ollivier-Hourmand,Jean-Pierre Zarski,Gisèle N'Kontchou,Sara Lemoinne,Lydie Humbert,Dominique Rainteau,Guillaume Lefèvre,Luc de Chaisemartin,Sylvie Chollet-Martin,Farid Gaouar,Farid-Hakeem Admane,Tabassome Simon,Raoul Poupon +32 more
TL;DR: Treating patients with primary biliary cholangitis with bezafibrate in addition to ursodeoxycholic acid resulted in a rate of complete biochemical response that was significantly higher than the rate with placebo and ursodespecific acid therapy.
Journal ArticleDOI
Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.
Guillaume Lefèvre,Luc Dauchet,Eric Hachulla,David Montani,Vincent Sobanski,Marc Lambert,Pierre-Yves Hatron,Marc Humbert,David Launay +8 more
TL;DR: Baseline hemodynamic measures of PAH severity, but not the period of time during which patients were included in the studies, correlated significantly with survival in patients with SSc-associated PAH, revealing a poor pooled 3-year survival rate.
Journal ArticleDOI
European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay.
Magdalena Krintus,Marek Koziński,Pascal Boudry,Nuria Estañ Capell,Ursula Köller,Karl J. Lackner,Guillaume Lefèvre,Lieselotte Lennartz,Johannes Lotz,Antonio Mora Herranz,Mads Nybo,Mario Plebani,Maria B. Sandberg,Wolfgang Schratzberger,Jessie Shih,Øyvind Skadberg,Ahmed Taoufik Chargui,Martina Zaninotto,Grazyna Sypniewska +18 more
TL;DR: The new ARCHITECT STAT hs-TnI assay with improved analytical features meets the criteria of high sensitive Tn test and will be a valuable diagnostic tool.
Journal ArticleDOI
Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies.
Laurent Arnaud,Laurent Arnaud,Alexis Mathian,Hervé Devilliers,Amelia Ruffatti,Maria G Tektonidou,Ricardo Forastiero,Vittorio Pengo,Marc Lambert,Guillaume Lefèvre,María Ángeles Martínez-Zamora,Juan Balasch,Denis Wahl,Zahir Amoura +13 more
TL;DR: The risk of first thrombotic event as well of first arterial thromBotic event is significantly decreased among SLE patients and asymptomatic aPL individuals treated by low-dose aspirin.
Journal ArticleDOI
Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis.
Vincent Sobanski,Luc Dauchet,Guillaume Lefèvre,Marc Lambert,Sandrine Morell-Dubois,Thierno Sy,Eric Hachulla,Pierre-Yves Hatron,David Launay,Sylvain Dubucquoi +9 more
TL;DR: A new SSc cohort is described and a systematic review and meta‐analysis is performed to assess the prevalence of anti–RNAP III in patients worldwide and the potential factors of variability.